MTNB Matinas BioPharma Holdings,...

NYSE matinasbiopharma.com


$ 1.90 $ 0.03 (1.6 %)    

Wednesday, 15-Oct-2025 15:59:52 EDT
QQQ $ 602.29 $ -1.66 (-0.27 %)
DIA $ 462.60 $ -1.92 (-0.41 %)
SPY $ 664.94 $ -1.70 (-0.25 %)
TLT $ 90.78 $ -0.30 (-0.33 %)
GLD $ 387.27 $ 1.52 (0.39 %)
$ 1.9
$ 1.87
$ 1.70 x 1
$ 2.06 x 35
$ 1.80 - $ 1.93
$ 0.47 - $ 4.25
29,138
na
9.67M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 matinas-biopharma-doubles-authorized-common-shares-to-500m-following-shareholder-approval

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year. On August 6, 2025, Matinas BioPharma Holdi...

 111-equity-group-increases-stake-to-517-in-matinas-biopharma-as-strategic-review-underway-including-asset-sale-of-mat2203-103m-cash-reported-which-would-equate-to-roughly-213-cash-per-share-value

111 Equity Group, LLC ("111 Equity") and its principal filed a Schedule 13D with the Securities and Exchange Commission...

 matinas-biopharma-receives-nyse-noncompliance-notice

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicati...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION